Loss of responsiveness to transforming growth factor β induces malignant transformation of nontumorigenic rat prostate epithelial cells

Cancer Research

Volumn 59, Issue 19, 1999, Pages 4834-4842

  Tang, Binwu ^a   De Castro, Katherine ^a   Barnes, Helen E ^a   Parks, W Tony ^a   Stewart, LaMonica ^a,b   Böttinger, Erwin P ^a,c   Danielpour, David ^a,d   Wakefield, Lalage M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRONECTIN; RNA; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; EXTRACELLULAR MATRIX; GENE REPRESSION; MALE; MALIGNANT TRANSFORMATION; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; PROSTATE EPITHELIUM; PROSTATE TUMOR; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; APOPTOSIS; CELL DIFFERENTIATION; CELL DIVISION; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; EPITHELIAL CELLS; EXTRACELLULAR MATRIX PROTEINS; GENE EXPRESSION REGULATION; HUMANS; MALE; MICE; MICE, NUDE; PROSTATE; PROSTATIC NEOPLASMS; RATS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RECOMBINANT PROTEINS; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA; TRANSPLANTATION, HETEROLOGOUS;

EID: 0033214970     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Roberts, A. B., and Sporn, M. B. The transforming growth factors-β. In: M. B. Sporn and A. B. Roberts (eds.), Handbook of Experimental Pharmacology. Peptide Growth Factors and Their Receptors, pp. 419-472. Berlin: Springer-Verlag, 1990.
2. Massagué. J. TGF-β signal transduction. Annu. Rev. Biochem., 67: 753-791, 1998.
3. 1 arrest, p53, and Rb. Cancer Res., 56: 3645-3650, 1996.
4. Massagué, J. The transforming growth factor-β family. Annu. Rev. Cell Biol., 6: 597-641, 1990.
5. Massagué, J. TGFβ signaling: receptors, transducers, and Mad proteins. Cell, 85: 947-950, 1996.
6. Heldin, C. H., Miyazono, K., and ten Dijke, P. TGF-β signalling from cell membrane to nucleus through SMAD proteins. Nature (Lond.), 390: 465-471, 1997.
7. Markowitz, S. D., and Roberts, A. B. Tumor suppressor activity of the TGF-β pathway in human cancers. Cytokine Growth Factor Rev., 7: 93-102, 1996.
8. Hata, A., Shi, Y., and Massagué, J. TGF-β signaling and cancer: structural and functional consequences of mutations in smads. Mol. Med. Today, 4: 257-262, 1998.
9. Reiss, M. Transforming growth factor-β and cancer: a love-hate relationship? Oncol. Res., 9: 447-457, 1997.
10. Böttinger, E. P., Jakubczak, J. L., Haines, D. C., Bagnall, K., and Wakefield, L. M. Transgenic mice overexpressing a dominant-negative mutant type 11 transforming growth factor β receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7,12-dimethylbenz-[a]-anthracene. Cancer Res., 57: 5564-5570, 1997.
11. Amendt, C., Schirmacher, P., Weber, H., and Blessing, M. Expression of a dominant negative type II TGF-β receptor in mouse skin results in an increase in carcinoma incidence and an acceleration of carcinoma development. Oncogene, 17: 25-34, 1998.
12. Sun, L., Wu, G., Willson, J. K., Zborowska, E., Yang, J., Rajkarunanayake, I., Wang, J., Gentry, L. E., Wang, X. F., and Brattain, M. G. Expression of transforming growth factor β type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells. J. Biol. Chem., 269: 26449-26455, 1994.
13. Sun, L., and Chen, C. Expression of transforming growth factor β type III receptor suppresses tumorigenicity of human breast cancer MDA-MB-231 cells. J. Biol. Chem., 272: 25367-25372, 1997.
14. Guo, Y., and Kyprianou, N. Overexpression of transforming growth factor (TGF) β1 type II receptor restores TGF-β1 sensitivity and signaling in human prostate cancer cells. Cell Growth Differ., 9: 185-193, 1998.
15. Zhu, Y., Richardson, J. A., Parada, L. F., and Graff, J. M. Smad3 mutant mice develop melastatic colorectal cancer. Cell, 94: 703-714, 1998.
16. Takaku, K., Oshima, M., Miyoshi, H., Matsui, M., Seldin, M. F., and Taketo, M. M. Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes. Cell, 92: 645-656, 1998.
17. Tang, B., Böttinger, E. P., Jakowlew, S. B., Bagnall, K. M., Mariano, J., Anver, M. R., Letterio, J. J., and Wakefield, L. M. Transforming growth factor-β1 is a new form of tumor suppressor with true haploid insufficiency. Nat. Med., 4: 802-807, 1998.
18. Landis, S. H., Murray, T., Bolden, S., and Wingo, P. A. Cancer statistics, 1998. CA Cancer J. Clin., 48: 6-29, 1998.
19. Kyprianou, N., and Isaacs, J. T. Identification of a cellular receptor for transforming growth factor-β in rat ventral prostate and its negative regulation by androgens. Endocrinology, 123: 2124-2131, 1988.
20. Timme, T. L., Truong, L. D., Slawin, K. M., Kadmon, D., Park, S. H., and Thompson, T. C. Mesenchymal-epithelial interactions and transforming growth factor-β1 expression during normal and abnormal prostatic growth. Microsc. Res. Tech., 30: 333-341, 1995.
21. Kim, I. Y., Ahn, H. J., Zelner, D. J., Park, L., Sensibar, J. A., and Lee, C. Expression and localization of transforming growth factor-β receptors type I and type II in the rat ventral prostate during regression. Mol. Endocrinol., 10: 107-115, 1996.
22. Martikainen, P., Kyprianou, N., and Isaacs, J. T. Effect of transforming growth factor-β1 on proliferation and death of rat prostatic cells. Endocrinology, 127: 2963-2968, 1990.
23. Danielpour, D., Kadomatsu, K., Anzano, M. A., Smith, J. M., and Sporn, M. B. Development and characterization of nontumorigenic and tumorigenic epithelial cell lines from rat dorsal-lateral prostate. Cancer Res., 54: 3413-3421, 1994.
24. Hsing, A. Y., Kadomatsu, K., Bonham, M. J., and Danielpour, D. Regulation of apoptosis induced by transforming growth factor-β1 in nontumorigenic rat prostatic epithelial cell lines. Cancer Res., 56: 5146-5149, 1996.
25. Eastham, J. A., Truong, L. D., Rogers, E., Kattan, M., Flanders, K. C., Scardino, P. T., and Thompson, T. C. Transforming growth factor-β1: comparative immuno-histochemical localization in human primary and metastatic prostate cancer. Lab. Investig.. 73: 628-635, 1995.
26. Williams, R. H., Stapleton, A. M. F., Yang, G., Truong. L. D., Rogers, E., Timme, T. L., Wheeler, T. M., Scardino, P. T., and Thompson, T. C. Reduced levels of transforming growth factor β receptor type II in human prostate cancer: an immunohistochemical study. Clin. Cancer Res., 2: 635-640, 1996.
27. Kim, I. Y., Ahn, H. J., Lang, S., Oefelein, M. G., Oyasu, R., Kozlowski, J. M., and Lee, C. Loss of expression of transforming growth factor-β receptors is associated with poor prognosis in prostate cancer patients. Clin. Cancer Res., 4: 1625-1630, 1998.
28. Kim, I. Y., Ahn, H. J., Zelner, D. J., Shaw, J. W., Sensibar, J. A., Kim, J. H., Kato, M., and Lee, C. Genetic change in transforming growth factor β (TGF-β) receptor type I gene correlates with insensitivity to TGF-β 1 in human prostate cancer cells. Cancer Res., 56: 44-48, 1996.
29. Ivanovic, V., Melman, A., Davis-Joseph, B., Valcic, M., and Geliebter, J. Elevated plasma levels of TGF-β 1 in patients with invasive cancer. Nat. Med., 1: 282-284, 1995.
30. Steiner, M. S., and Barrack, E. R. Transforming growth factor-β1 overproduction in prostate cancer: effects on growth in vivo and in vitro, Mol. Endocrinol., 6: 15-25, 1992.
31. Danielpour, D. Transdifferentiation of NRP152 rat prostatic basal epithelial cells toward a luminal phenotype: regulation by glucocorticoid, insulin-like growth factor-I and transforming growth factor-β. J. Cell Sci., 112: 169-179, 1999.
32. Hayward, S. W., Haughney, P. C., Lopes, E. S., Danielpour, D., and Cunha, G. R. The rat epithelial cell line NRP-152 can differentate in vivo in response to its stromal environment. Prostate, 39: 205-212, 1999.
33. Wrana, J. L., Attisano, L., Carcamo, J., Zentella, A., Doody, J., Laiho, M., Wang, X. F., and Massagué, J. TGF β signals through a heteromeric protein kinase receptor complex. Cell, 71: 1003-1014, 1992.
34. Danielpour, D. Induction of transforming growth factor-β autocrine activity by all-trans-retinoic acid and 1α,25-dihydroxyvitamin D3 in NRP-152 rat prostatic epithelial cells. J. Cell Physiol., 166: 231-239, 1996.
35. Pear, W. S., Nolan, G. P., Scott, M. L., and Baltimore, D. Production of high-titer helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci. USA, 90: 8392-8396, 1993.
36. Bonham, M. J., and Danielpour, D. Improved purification and yields of RNA by RNeasy. Biotechniques, 21: 57-60, 1996.
37. Church, G. M., and Gilbert, W. Genomic sequencing. Proc. Natl. Acad. Sci. USA, 81: 1991-1995, 1984.
38. Alley, M. C., Scudiero, D. A., Monks, A., Hursey, M. L., Czerwinski, M. J., Fine, D. L., Abbott, B. J., Mayo, J. G., Shoemaker, R. H., and Boyd, M. R. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res., 48: 589-601, 1988.
39. Danielpour, D., Dart, L. L., Flanders, K. C., Roberts, A. B., and Sporn, M. B. Immunodetection and quantitation of the two forms of transforming growth factor-β (TGF-β 1 and TGF-β 2) secreted by cells in culture. J. Cell Physiol., 138: 79-86, 1989.
40. Ide, H., Yoshida, T., Matsumoto, N., Aoki, K., Osada, Y., Sugimura, T., and Terada, M. Growth regulation of human prostate cancer cells by bone morphogenetic protein-2. Cancer Res., 57: 5022-5027, 1997.
41. Ignotz, R. A., Endo, T., and Massagué, J. Regulation of fibronectin and type I collagen mRNA levels by transforming growth factor-β. J. Biol. Chem., 262: 6443-6446, 1987.
42. Chen, R. H., Ebner, R., and Derynck, R. Inactivation of the type II receptor reveals two receptor pathways for the diverse TGF-β activities. Science (Washington DC), 260: 1335-1338, 1993.
43. Geiser, A. G., Burmester, J. K., Webbink, R., Roberts, A. B., and Sporn, M. B. Inhibition of growth by transforming growth factor-ß following fusion of two nonresponsive human carcinoma cell lines. Implication of the type II receptor in growth inhibitory responses. J. Biol. Chem., 267: 2588-2593, 1992.
44. Morton, D. M., and Barrack, E. R. Modulation of transforming growth factor β1 effects on prostate cancer cell proliferation by growth factors and extracellular matrix. Cancer Res., 55: 2596-2602, 1995.
45. Pierce, G. B., and Speers, W. C. Tumors as caricatures of the process of tissue renewal: prospects for therapy by directing differentiation. Cancer Res., 48: 1996-2004, 1988.
46. Grady, W. M., Rajput, A., Myeroff, L., Liu, D. F., Kwon, K., Willis, J., and Markowitz, S. Mutation of the type II transforming growth factor-β receptor is coincident with the transformation of human colon adenomas to malignant carcinomas. Cancer Res., 58: 3101-3104, 1998.
47. Guinan, P., Didomenico, D., Brown, J., Shaw, M., Sharifi, R., Ray, V., Shott, S., and Rubenstein, M. The effect of androgen deprivation on malignant and benign prostate tissue. Med. Oncol., 14: 145-152, 1997.
48. Altieri, P., Zegarra, M. O., Galietta, L. J., Tarelli, L. T., Sessa, A., and Ghiggeri, G. M. Transforming growth factor β blocks cystogenesis by MDCK epithelium in vitro by enhancing the paracellular flux: implication of collagen V. J. Cell Physiol., 177: 214-223, 1998.
49. Oft, M., Heider, K. H., and Beug, H. TGFβ signaling is necessary for carcinoma cell invasiveness and metastasis. Curr. Biol., 8: 1243-1252, 1998.
50. Yin, J. J., Selander, K., Chirgwin, J. M., Dallas, M., Grubbs, B. G., Wieser, R., Massagué, J., Mundy, G. R., and Guise, T. A. TGF-β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone métastases development. J. Clin. Investig., 103,-197-206, 1999.
51. Portella, G., Cumming, S. A., Liddell, J., Cui, W., Ireland, H., Akhurst, R. J., and Balmain, A. Transforming growth factor β is essential for spindle cell conversion of mouse skin carcinoma in vivo: implications for tumor invasion. Cell Growth Differ., 9: 393-404, 1998.
52. Torre-Amione, G., Beauchamp, R. D., Koeppen, H., Park, B. H., Schreiber, H., Moses, H. L., and Rowley, D. A. A highly immunogenic tumor transfected with a murine transforming growth factor type β1 cDNA escapes immune surveillance. Proc. Natl. Acad. Sci. USA, 87: 1486-1490, 1990.
53. Fajardo, L. F., Prionas, S. D., Kwan, H. H., Kowalski, J., and Allison, A. C. Transforming growth factor β1 induces angiogenesis in vivo with a threshold pattern. Lab. Investig., 74: 600-608, 1996.
54. McCaffrey, T. A., Consigli, S., Du, B., Falcone, D. J., Sanborn, T. A., Spokojny, A. M., and Bush, H. L., Jr. Decreased type II/type I TGF-β receptor ratio in cells derived from human atherosclerotic lesions. Conversion from an antiproliferative to profibrotic response to TGF-β1. J. Clin. Investig., 96: 2667-2675, 1995.
55. Centrella, M., Casinghino, S., Kim, J., Pham, T., Rosen, V., Wozney, J., and McCarthy, T. L. Independent changes in type I and type II receptors for transforming growth factor β induced by bone morphogenetic protein 2 parallel expression of the osteoblast phenotype. Mol. Cell Biol., 15: 3273-3281, 1995.